Articles tagged "Kidney transplantation"

2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
L. Bowman,¹ T. Horwedel,¹ J. Hagopian,¹ B. Bone,² H. Wijeweera,² D. Brennan.²
¹Barnes-Jewish Hospital, St. Louis; ²Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…
2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Y. Watarai,¹ M. Okada,¹ K. Futamura,¹ K. Ito,¹ T. Yamamoto,¹ M. Tsujita,¹ T. Hiramitsu,¹ N. Goto,¹ S. Narumi,¹ T. Kobayashi.²
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
2015 American Transplant Congress
Medication Adherence in Adolescents With Kidney Transplant and Chronic Kidney Disease: Patient/Caregiver Report Vs. Provider Perception
C. Pruette,¹ T. Brady,¹ S. Mendley,² B. Fivush,¹ S. Tuchman,³ A. Green,¹ M. Eakin,¹ K. Riekert.¹
¹Johns Hopkins University School of Medicine, Baltimore, MD; ²University of Maryland School of Medicine, Baltimore, MD; ³Children's National Medical Center, Washington, DC.
Background: Medication adherence in adolescent kidney transplant (KT) recipients is poor, with non-adherence (NA) ranging from 5-71%, and NA is associated with poor graft survival.…
2015 American Transplant Congress
Clinical Course of Pre-Existing Monoclonal Gammopathies Following Kidney Transplant
C. Johnson.
Nephrology, University of Washington, Seattle, WA.
INTRODUCTIONThe progression of monoclonal gammopathies following kidney transplant is not well described. Previous single-center retrospective data suggested that the course for a monoclonal gammopathy of…
2015 American Transplant Congress
HLA Broad Antigen and Eplet Mismatches in Determining the Risk of Acute Rejection After Kidney Transplantation
H. Do Nguyen,¹ W. Lim,^1,2 J. Chapman,³ J. Craig,^3,4 G. Wong.^3,4
¹School of Medicine and Pharmacology, University of Western Australia, Crawley, Western Australia, Australia; ²Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; ³Nephrology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia; ⁴School of Medicine, University of New South Wales, Sydney, New South Wales, Australia.
Aim: To determine the clinical relevance of HLA-ABDR broad antigen and eplet matching for predicting acute rejection after kidney transplantation.Background: HLAMatchmaker determines structurally HLA compatibility…
2015 American Transplant Congress
Donor-Specific Alloantibody After Positive Crossmatch Kidney Transplantation With Eculizumab (EC): Correlation With Transplant Glomerulopathy and Graft Failure
C. Schinstock,¹ F. Cosio,¹ L. Cornell,¹ M. Gandhi,¹ M. Everly,² M. Stegall.¹
¹Mayo Clinic, Rochester, MN; ²Paul Terasaki Foundation, Los Angeles, CA.
Introduction. EC (C5 blockade) reduces the incidence of early clinical acute antibody mediated rejection (AMR) after +XMKTx, but does not prevent chronic AMR. We examined…
2015 American Transplant Congress
Multicenter Validation of a Molecular Diagnostic for Antibody-Mediated Rejection in Formalin-Fixed Paraffin-Embedded Human Renal Allograft Biopsies
B. Adam,¹ B. Afzali,¹ N. Shah,¹ K. Dominy,² R. Gill,¹ L. Hidalgo,¹ P. Campbell,¹ C. Roufosse,² M. Mengel,¹ B. Sis.¹
¹University of Alberta, Edmonton, Canada; ²Imperial College, London, United Kingdom.
Background: In 2013, the Banff classification adopted molecular diagnostics as an adjunct for the diagnosis of antibody-mediated rejection (ABMR) in renal allografts. The NanoString gene…
2015 American Transplant Congress
CHBP Suppresses Acute Rejection by Inhibition Maturation of Dendritic Cells though Jak-2/STAT3/SOCS1 Signal in Rat Kidney Transplantation
C. Yang,¹ Y. Zhang,¹ J. Wang,¹ L. Li,¹ L. Wang,² M. Xu,¹ Y. Long,³ R. Rong,¹ T. Zhu.¹
¹Urology, Zhongshan Hospital, Fudan University, Shanghai, China; ²Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, China; ³CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Background. Renal acute rejection (AR) affects both allografts and recipients survival. We recently synthesized a novel proteolysis-resistant cyclic helix B peptide (CHBP), which exerts promising…
2015 American Transplant Congress
Targeting Complement Pathways During Ischemia and Reperfusion: Implications for the Prevention of Delayed Graft Function
Z. Yu,¹ S. Qi,² M. Lasaro,¹ K. Bouchard,¹ C. Dow,¹ K. Moore,¹ Z. Wu,² A. Barama,² J. Xu,² K. Johnson,¹ A. Marozsan,¹ Y. Wang.¹
¹Pre-Clinical Sciences, Alexion Pharmaceutical Inc., Cheshire, CT; ²Department of Surgery, Hôpital Notre Dame and Université de Montréal, Montréal, QC, Canada.
Complement system plays a critical role in ischemia-reperfusion injury (IRI), and contributes to DGF. The aim of this study was to evaluate the effects of…
2015 American Transplant Congress
Deceased Donor Kidney Transplantation Without Calcineurin Inhibitors or Steroids
A. Kirk,^1,2 A. Guasch,¹ S. Mead,¹ A. Ghali,¹ A. Mehta,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson.¹
¹Transplant Center, Emory University, Atlanta, GA; ²Surgery, Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…